• Viking Therapeutics launched a Phase 1 single-ascending-dose trial of VK3019, a dual amylin and calcitonin receptor agonist for weight loss.
• No results have been presented; the study will assess safety and tolerability in healthy adults with BMI ≥30.
• Exploratory readouts will track early signals of weight change following a single dose.
• The start broadens Viking’s obesity pipeline alongside ongoing Phase 3 VANQUISH trials of weekly injectable VK2735 in obesity and type 2 diabetes.
• Viking plans to start a Phase 3 trial of an oral tablet version of VK2735 later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606240705PR_NEWS_USPR_____LA90724) on June 24, 2026, and is solely responsible for the information contained therein.